LivingGLP1
Study S002604

Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration
NCT04272359
Acronym
Sulfa-Zero
Study type
OBSERVATIONAL
Status
UNKNOWN
Enrollment
138
Start
2019-05-06
Primary completion
2021-10-06
Lead sponsor
University of Milan
Conditions
T2DM (Type 2 Diabetes Mellitus); Diet, Healthy; Renal Function Disorder; Albuminuria
Interventions
DRUG:Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
Results posted
FALSE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Concentration of the glyco-metabolic parameters [12 months]
  • Therapeutic adherence [12 months]
  • Long-term diabetes complications [12 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0026731Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M, Diabetes, obesity & metabolism
2013Randomized trialPMID 22985213DOIregistry reference BACKGROUND:22985213
R0020062Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA, The American journal of medicine
2011Narrative reviewPMID 21194578DOIregistry reference BACKGROUND:21194578
R0027526Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A, Lancet (London, England)
2009Randomized trialPMID 18819705DOIregistry reference BACKGROUND:18819705